<DOC>
	<DOCNO>NCT01732354</DOCNO>
	<brief_summary>The investigator aim clarify issue adequate duration consolidation period Chronic hepatitis B infection antiviral treatment Tenofovir could strike balance durable HBeAg seroconversion avoid long-term inevitable serological virological recurrence .</brief_summary>
	<brief_title>Study Consolidation Period Chronic Hepatitis B</brief_title>
	<detailed_description>According practice guideline American Association Study Liver Diseases , patient HBeAg-positive chronic hepatitis B , treatment continue patient achieve HBeAg seroconversion undetectable serum HBV DNA complete least 6 month additional treatment appearance anti-HBe . Also several current guideline anti-viral treatment chronic hepatitis B infection suggest nucleos ( ) ide analogue treatment stop follow 6 12 month consolidation therapy HBeAg seroconversion . However , paucity data available long-term durability Tenofovir induce HBeAg seroconversion well antiviral treatment associate resistance risk . 2 . Primary end point : HBeAg seroconversion define loss HBeAg concurrent appearance HBeAb . Serological recurrence define reappearance HBeAg . Virological recurrence define increase HBV DNA level great 10,000 copies/mL HBeAg seroconversion previously HBV DNA level less 10,000 copies/mL . 3 . Aims : To clarify issue adequate duration consolidation period could strike balance durable HBeAg seroconversion avoid long-term inevitable serological virological recurrence . 4 . Study design : A single-center cohort study randomly allocate two different extend TDF treatment period HBeAg seroconversion - 12 month , 18 month across patient group . Then data collect outcome specific follow-up time .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>adult patient chronic HBV infection ( HBsAgpositivity least six month HBeAgpositivity least three month ) serum HBV DNA level â‰¥1000000 copies/ml ( Cobas Amplicor HBV Monitor assay ) screen well serum ALT level &gt; 1.3 time ULN ( 43 IU/L ) least two occasion previous 6 month screen . coinfection HCV , HDV , HIV treatment ( pegylated ) interferon nucleos ( ) ide analogues less six month start Tenofovir treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Hepatitis B virus , Tenofovir</keyword>
</DOC>